<DOC>
	<DOCNO>NCT01888107</DOCNO>
	<brief_summary>The purpose study assess maintenance antipsychotic efficacy safety risperidone long-acting injectable ( RLAI ) patient schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) schizoaffective ( mixed psychiatric disorder relate complex psychotic state feature schizophrenia mood disorder bipolar disorder ) disorder receive treatment antipsychotic medication require long-term antipsychotic therapy . The secondary aim investigate prospectively ( study start present condition population individual follow future ) prevalence patient meet standardized remission criterion ( accord Andreasen et al . criterion ) psychopathological , psychosocial subjective predictor achieve remission .</brief_summary>
	<brief_title>Maintenance Efficacy With Risperidone Long Acting Injectable ( R-LAI ) Patients With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description>This prospective , open-label , ( people know identity intervention ) , single-arm study conduct 47 site Italy January 2005 April 2007 . Approximately 338 patient schizophrenia schizoaffective disorder receive treatment antipsychotic medication require long-term antipsychotic therapy switch directly RLAI without oral risperidone run-in ( elapsed time trial start treatment give patient study ) . They consider either optimally treat symptom-free . Patients either hospitalized living residential structure time enrollment well throughout study . The maximum duration study participation 52 week . Patient safety monitor throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Schizophrenia schizoaffective disorder accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) Required longterm antipsychotic therapy time recruitment Symptomatically stable take dose antipsychotic agent least one month baseline visit ( consider stable appreciable change symptom previous month , regardless severity symptom ) Patients legal representative provide write informed consent prior enrollment study Patients receive clozapine previous 3 month Participated investigational drug trial previous 30 day Previously show either intolerant nonresponsive risperidone therapy Presence serious unstable medical condition , history current symptom tardive dyskinesia history neuroleptic malignant syndrome Pregnant breastfeeding ; female patient childbearing potential use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Antipsychotics</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Long-acting injectable</keyword>
</DOC>